Teva Pharmaceuticals
TEVA
438 hedge funds and large institutions have $4.81B invested in Teva Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 140 increasing their positions, 117 reducing their positions, and 53 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 117
17% more capital invested
Capital invested by funds: $4.12B → $4.81B (+$693M)
1% more call options, than puts
Call options by funds: $383M | Put options by funds: $377M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0.53% less ownership
Funds ownership: 47.19% → 46.66% (-0.53%)
3% less funds holding
Funds holding: 450 → 438 (-12)
13% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$73M |
| 2 |
EP
Eversept Partners
New York
|
+$15.4M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$15.3M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$14.9M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
-$93.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.3M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$20.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.7M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$15.2M |
TEVA Hedge Fund Activity: Q1 2022 in Review
438 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2022, worth a combined $4.81B — up 17% from $4.12B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of TEVA and 46 opened new positions — a net loss of 7 holders — while 117 trimmed existing stakes and 140 added.
The largest buyer was Millennium Management, adding an estimated $73M. The largest seller was Lingotto Investment Management, exiting entirely with an estimated $93.9M sold.
- 438 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2022, down from 450 in Q4 2021.
- Funds reported $4.81B of Teva Pharmaceuticals stock for Q1 2022, up 17% quarter-over-quarter.
- 46 funds opened new Teva Pharmaceuticals positions in Q1 2022 and 53 closed out, a net change of -7 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2022 was Millennium Management, an estimated $73M added.
- The largest Teva Pharmaceuticals seller in Q1 2022 was Lingotto Investment Management, an estimated $93.9M sold.
Based on aggregated 13F filings for Q1 2022.